Ambit Biosciences Corp (AMBI) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
11080 ROSELLE STREET SAN DIEGO, CA 92121 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 6/30/2014 Q2 | 3/31/2014 Q1 | 12/31/2013 Q4 | 9/30/2013 Q3 | 6/30/2013 Q2 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 61,853 | 71,189 | 78,856 | 85,285 | |||
| Cash and cash equivalent | 61,853 | 71,189 | 78,856 | 85,285 | |||
| Receivables | 1,000 | ||||||
| Other undisclosed current assets | 1,508 | 911 | 1,031 | 935 | |||
| Total current assets: | 63,361 | 73,100 | 79,887 | 86,220 | |||
| Noncurrent Assets | |||||||
| Property, plant and equipment | 823 | 785 | 816 | 799 | |||
| Restricted cash and investments | 63 | 63 | 63 | 63 | |||
| Total noncurrent assets: | 886 | 848 | 879 | 862 | |||
| TOTAL ASSETS: | 64,247 | 73,948 | 80,766 | 87,082 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 5,765 | 9,557 | 6,397 | 7,106 | |||
| Employee-related liabilities | 1,461 | 1,997 | 1,702 | 1,323 | |||
| Accounts payable | 1,516 | ||||||
| Accounts payable and other accrued liabilities | 4,304 | 4,711 | 4,695 | 5,783 | |||
| Accrued liabilities | 1,333 | ||||||
| Debt | 1,798 | ||||||
| Deferred revenue and credits | 115 | 6,947 | |||||
| Other undisclosed current liabilities | 9,122 | 6,801 | 15,623 | 6,965 | |||
| Total current liabilities: | 15,002 | 16,358 | 22,020 | 22,816 | |||
| Noncurrent Liabilities | |||||||
| Total liabilities: | 15,002 | 16,358 | 22,020 | 22,816 | |||
| Equity | |||||||
| Equity, attributable to parent, including: | 49,245 | 57,590 | 58,746 | 64,266 | |||
| Common stock | 18 | 18 | 18 | 18 | |||
| Additional paid in capital | 306,872 | 306,064 | 304,932 | 304,383 | |||
| Accumulated other comprehensive loss | (481) | (326) | (83) | (83) | |||
| Accumulated deficit | (257,164) | (248,166) | (246,121) | (240,052) | |||
| Warrants and rights outstanding | |||||||
| Other undisclosed equity, attributable to parent | |||||||
| Total equity: | 49,245 | 57,590 | 58,746 | 64,266 | |||
| TOTAL LIABILITIES AND EQUITY: | 64,247 | 73,948 | 80,766 | 87,082 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 6/30/2014 Q2 | 3/31/2014 Q1 | 12/31/2013 Q4 | 9/30/2013 Q3 | 6/30/2013 Q2 | ||
|---|---|---|---|---|---|---|
| Revenues | 11,547 | |||||
| Gross profit: | 11,547 | |||||
| Operating expenses | (9,565) | (9,424) | (5,060) | (8,861) | ||
| Other undisclosed operating income | 32 | 1,276 | 7,678 | |||
| Operating income (loss): | (9,533) | (8,148) | 2,618 | 2,686 | ||
| Nonoperating income (expense) | 536 | 6,103 | (8,717) | 2,474 | ||
| Interest and debt expense | (53) | (108) | ||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (8,997) | (2,045) | (6,152) | 5,052 | ||
| Other undisclosed income from continuing operations before income taxes | 53 | 108 | ||||
| Income (loss) from continuing operations before income taxes: | (8,997) | (2,045) | (6,099) | 5,160 | ||
| Income tax expense (benefit) | (1) | 30 | ||||
| Income (loss) from continuing operations: | (8,998) | (2,045) | (6,069) | 5,160 | ||
| Income (loss) before gain (loss) on sale of properties: | (8,998) | (2,045) | (6,069) | 5,160 | ||
| Net income (loss): | (8,998) | (2,045) | (6,069) | 5,160 | ||
| Net income attributable to noncontrolling interest | 12 | |||||
| Other undisclosed net loss attributable to parent | (24) | |||||
| Net income (loss) attributable to parent: | (8,998) | (2,045) | (6,069) | 5,148 | ||
| Preferred stock dividends and other adjustments | (1,315) | |||||
| Other undisclosed net loss available to common stockholders, basic | (211) | |||||
| Net income (loss) available to common stockholders, basic: | (8,998) | (2,045) | (6,069) | 3,622 | ||
| Other undisclosed net loss available to common stockholders, diluted | (528) | |||||
| Net income (loss) available to common stockholders, diluted: | (9,526) | (2,045) | (6,069) | 3,622 | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 6/30/2014 Q2 | 3/31/2014 Q1 | 12/31/2013 Q4 | 9/30/2013 Q3 | 6/30/2013 Q2 | ||
|---|---|---|---|---|---|---|
| Net income (loss): | (8,998) | (2,045) | (6,069) | 5,160 | ||
| Other undisclosed comprehensive income (loss) | (155) | (243) | 3 | |||
| Comprehensive income (loss): | (9,153) | (2,288) | (6,069) | 5,163 | ||
| Comprehensive loss, net of tax, attributable to noncontrolling interest | (12) | |||||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 61 | |||||
| Comprehensive income (loss), net of tax, attributable to parent: | (9,153) | (2,227) | (6,069) | 5,151 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.